ArticleFrontiers in pharmacology2024
Leveraging AI to automate detection and quantification of extrachromosomal DNA to decode drug responses.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Plasticity of extrachromosomal DNA segregation during drug adaptation.Nature communications · 2026Article
- Extrachromosomal DNA Gives Cancer a New Evolutionary Pathway.Research square · 2026Article
- Research Advances of Extrachromosomal Circular DNA in Breast Cancer.Cancer medicine · 2025Review
- The role of extrachromosomal DNA in tumorigenesis and progression.Frontiers in oncology · 2025Review
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
Abstract
Introduction: Traditional drug discovery efforts primarily target rapid, reversible protein-mediated adaptations to counteract cancer cell resistance. However, cancer cells also utilize DNA-based strategies, often perceived as slow, irreversible changes like point mutations or drug-resistant clone selection. Extrachromosomal DNA (ecDNA), in contrast, represents a rapid, reversible, and predictable DNA alteration critical for cancer's adaptive response. Methods: In this study, we developed a novel post-processing pipeline for automated detection and quantification of ecDNA in metaphase Fluorescence in situ Hybridization (FISH) images, leveraging the Microscopy Image Analyzer (MIA) tool. This pipeline is tailored to monitor ecDNA dynamics during drug treatment. Results: Our approach effectively quantified ecDNA changes, providing a robust framework for analyzing the adaptive responses of cancer cells under therapeutic pressure. Discussion: The pipeline not only serves as a valuable resource for automating ecDNA detection in metaphase FISH images but also highlights the role of ecDNA in facilitating swift and reversible adaptation to epigenetic remodeling agents such as JQ1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.